AMGEN INC (AMGN) Fundamental Analysis & Valuation

NASDAQ:AMGN • US0311621009

Current stock price

351.02 USD
-4.58 (-1.29%)
At close:
352 USD
+0.98 (+0.28%)
After Hours:

This AMGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. AMGN Profitability Analysis

1.1 Basic Checks

  • In the past year AMGN was profitable.
  • In the past year AMGN had a positive cash flow from operations.
  • AMGN had positive earnings in each of the past 5 years.
  • Each year in the past 5 years AMGN had a positive operating cash flow.
AMGN Yearly Net Income VS EBIT VS OCF VS FCFAMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

1.2 Ratios

  • The Return On Assets of AMGN (8.51%) is better than 92.84% of its industry peers.
  • The Return On Equity of AMGN (89.06%) is better than 99.23% of its industry peers.
  • The Return On Invested Capital of AMGN (16.85%) is better than 96.52% of its industry peers.
  • AMGN had an Average Return On Invested Capital over the past 3 years of 14.35%. This is significantly below the industry average of 27.63%.
  • The 3 year average ROIC (14.35%) for AMGN is below the current ROIC(16.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.51%
ROE 89.06%
ROIC 16.85%
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
AMGN Yearly ROA, ROE, ROICAMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50 100 150

1.3 Margins

  • AMGN has a better Profit Margin (20.98%) than 93.04% of its industry peers.
  • AMGN's Profit Margin has declined in the last couple of years.
  • AMGN's Operating Margin of 34.19% is amongst the best of the industry. AMGN outperforms 96.33% of its industry peers.
  • AMGN's Operating Margin has improved in the last couple of years.
  • AMGN has a Gross Margin of 73.30%. This is amongst the best in the industry. AMGN outperforms 81.62% of its industry peers.
  • AMGN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 34.19%
PM (TTM) 20.98%
GM 73.3%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
AMGN Yearly Profit, Operating, Gross MarginsAMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AMGN Health Analysis

2.1 Basic Checks

  • AMGN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, AMGN has more shares outstanding
  • The number of shares outstanding for AMGN has been reduced compared to 5 years ago.
  • The debt/assets ratio for AMGN has been reduced compared to a year ago.
AMGN Yearly Shares OutstandingAMGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
AMGN Yearly Total Debt VS Total AssetsAMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.2 Solvency

  • AMGN has a debt to FCF ratio of 6.74. This is a slightly negative value and a sign of low solvency as AMGN would need 6.74 years to pay back of all of its debts.
  • AMGN has a better Debt to FCF ratio (6.74) than 90.52% of its industry peers.
  • AMGN has a Debt/Equity ratio of 5.78. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 5.78, AMGN is doing worse than 82.40% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 5.78
Debt/FCF 6.74
Altman-Z N/A
ROIC/WACC1.86
WACC9.06%
AMGN Yearly LT Debt VS Equity VS FCFAMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

2.3 Liquidity

  • AMGN has a Current Ratio of 1.14. This is a normal value and indicates that AMGN is financially healthy and should not expect problems in meeting its short term obligations.
  • AMGN has a Current ratio of 1.14. This is amonst the worse of the industry: AMGN underperforms 85.11% of its industry peers.
  • A Quick Ratio of 0.90 indicates that AMGN may have some problems paying its short term obligations.
  • AMGN's Quick ratio of 0.90 is on the low side compared to the rest of the industry. AMGN is outperformed by 86.65% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.9
AMGN Yearly Current Assets VS Current LiabilitesAMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. AMGN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 10.24% over the past year.
  • Measured over the past 5 years, AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 5.65% on average per year.
  • The Revenue has grown by 9.95% in the past year. This is quite good.
  • AMGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.65% yearly.
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%

3.2 Future

  • Based on estimates for the next years, AMGN will show a small growth in Earnings Per Share. The EPS will grow by 4.89% on average per year.
  • Based on estimates for the next years, AMGN will show a small growth in Revenue. The Revenue will grow by 3.17% on average per year.
EPS Next Y4.51%
EPS Next 2Y4.28%
EPS Next 3Y4.5%
EPS Next 5Y4.89%
Revenue Next Year4.1%
Revenue Next 2Y3.29%
Revenue Next 3Y3.03%
Revenue Next 5Y3.17%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMGN Yearly Revenue VS EstimatesAMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B 40B
AMGN Yearly EPS VS EstimatesAMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

6

4. AMGN Valuation Analysis

4.1 Price/Earnings Ratio

  • AMGN is valuated correctly with a Price/Earnings ratio of 16.06.
  • Based on the Price/Earnings ratio, AMGN is valued cheaper than 95.16% of the companies in the same industry.
  • AMGN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.78, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 15.37, AMGN is valued correctly.
  • 95.94% of the companies in the same industry are more expensive than AMGN, based on the Price/Forward Earnings ratio.
  • AMGN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.06
Fwd PE 15.37
AMGN Price Earnings VS Forward Price EarningsAMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 94.58% of the companies in the same industry are more expensive than AMGN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 23.36
EV/EBITDA N/A
AMGN Per share dataAMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AMGN does not grow enough to justify the current Price/Earnings ratio.
  • AMGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.56
PEG (5Y)2.84
EPS Next 2Y4.28%
EPS Next 3Y4.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. AMGN Dividend Analysis

5.1 Amount

  • AMGN has a Yearly Dividend Yield of 2.83%.
  • Compared to an average industry Dividend Yield of 1.11, AMGN pays a better dividend. On top of this AMGN pays more dividend than 98.84% of the companies listed in the same industry.
  • AMGN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.83.
Industry RankSector Rank
Dividend Yield 2.83%

5.2 History

  • On average, the dividend of AMGN grows each year by 9.41%, which is quite nice.
  • AMGN has paid a dividend for at least 10 years, which is a reliable track record.
  • AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.41%
Div Incr Years14
Div Non Decr Years14
AMGN Yearly Dividends per shareAMGN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6 8

5.3 Sustainability

  • The dividend of AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y4.28%
EPS Next 3Y4.5%
AMGN Yearly Income VS Free CF VS DividendAMGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

More info and screens

Find the best dividend stocksShow peers with best dividend

AMGN Fundamentals: All Metrics, Ratios and Statistics

AMGEN INC

NASDAQ:AMGN (4/10/2026, 8:05:58 PM)

After market: 352 +0.98 (+0.28%)

351.02

-4.58 (-1.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-03
Earnings (Next)04-30
Inst Owners85.27%
Inst Owner Change0.01%
Ins Owners0.07%
Ins Owner Change3.94%
Market Cap189.22B
Revenue(TTM)36.75B
Net Income(TTM)7.71B
Analysts70.7
Price Target360.51 (2.7%)
Short Float %2.66%
Short Ratio4.96
Dividend
Industry RankSector Rank
Dividend Yield 2.83%
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP0%
Div Incr Years14
Div Non Decr Years14
Ex-Date05-15
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.92%
Min EPS beat(2)9.56%
Max EPS beat(2)10.28%
EPS beat(4)4
Avg EPS beat(4)10.8%
Min EPS beat(4)9.56%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)6.29%
EPS beat(12)11
Avg EPS beat(12)5.41%
EPS beat(16)14
Avg EPS beat(16)4.51%
Revenue beat(2)2
Avg Revenue beat(2)3.3%
Min Revenue beat(2)2.11%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)4
Avg Revenue beat(8)0.19%
Revenue beat(12)5
Avg Revenue beat(12)-0.22%
Revenue beat(16)6
Avg Revenue beat(16)-0.27%
PT rev (1m)0.07%
PT rev (3m)7.72%
EPS NQ rev (1m)-1.06%
EPS NQ rev (3m)-6.15%
EPS NY rev (1m)0.05%
EPS NY rev (3m)1.95%
Revenue NQ rev (1m)-0.23%
Revenue NQ rev (3m)-0.66%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)2.32%
Valuation
Industry RankSector Rank
PE 16.06
Fwd PE 15.37
P/S 5.15
P/FCF 23.36
P/OCF 19
P/B 21.86
P/tB N/A
EV/EBITDA N/A
EPS(TTM)21.85
EY6.22%
EPS(NY)22.84
Fwd EY6.51%
FCF(TTM)15.03
FCFY4.28%
OCF(TTM)18.47
OCFY5.26%
SpS68.17
BVpS16.06
TBVpS-59.91
PEG (NY)3.56
PEG (5Y)2.84
Graham Number88.86
Profitability
Industry RankSector Rank
ROA 8.51%
ROE 89.06%
ROCE 19.3%
ROIC 16.85%
ROICexc 19.6%
ROICexgc 73.08%
OM 34.19%
PM (TTM) 20.98%
GM 73.3%
FCFM 22.04%
ROA(3y)6.63%
ROA(5y)7.92%
ROE(3y)88.81%
ROE(5y)106.67%
ROIC(3y)14.35%
ROIC(5y)15.45%
ROICexc(3y)16.88%
ROICexc(5y)18.44%
ROICexgc(3y)72.7%
ROICexgc(5y)79.08%
ROCE(3y)16.43%
ROCE(5y)17.69%
ROICexgc growth 3Y-3.21%
ROICexgc growth 5Y2.03%
ROICexc growth 3Y4.63%
ROICexc growth 5Y5.17%
OM growth 3Y4.6%
OM growth 5Y4.15%
PM growth 3Y-5.54%
PM growth 5Y-5.99%
GM growth 3Y2.93%
GM growth 5Y1.72%
F-Score7
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 5.78
Debt/FCF 6.74
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 5.06%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 105.05%
Current Ratio 1.14
Quick Ratio 0.9
Altman-Z N/A
F-Score7
WACC9.06%
ROIC/WACC1.86
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4.09%
Cap/Sales(5y)3.84%
Profit Quality(3y)156.25%
Profit Quality(5y)149.01%
High Growth Momentum
Growth
EPS 1Y (TTM)10.24%
EPS 3Y7.29%
EPS 5Y5.65%
EPS Q2Q%-0.38%
EPS Next Y4.51%
EPS Next 2Y4.28%
EPS Next 3Y4.5%
EPS Next 5Y4.89%
Revenue 1Y (TTM)9.95%
Revenue growth 3Y11.77%
Revenue growth 5Y7.65%
Sales Q2Q%8.58%
Revenue Next Year4.1%
Revenue Next 2Y3.29%
Revenue Next 3Y3.03%
Revenue Next 5Y3.17%
EBIT growth 1Y73.11%
EBIT growth 3Y16.9%
EBIT growth 5Y12.12%
EBIT Next Year31.72%
EBIT Next 3Y9.49%
EBIT Next 5Y8.55%
FCF growth 1Y-22.07%
FCF growth 3Y-2.67%
FCF growth 5Y-3.91%
OCF growth 1Y-13.33%
OCF growth 3Y0.81%
OCF growth 5Y-1.05%

AMGEN INC / AMGN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for AMGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to AMGN.


What is the valuation status of AMGEN INC (AMGN) stock?

ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.


How profitable is AMGEN INC (AMGN) stock?

AMGEN INC (AMGN) has a profitability rating of 8 / 10.


What are the PE and PB ratios of AMGEN INC (AMGN) stock?

The Price/Earnings (PE) ratio for AMGEN INC (AMGN) is 16.06 and the Price/Book (PB) ratio is 21.86.


How financially healthy is AMGEN INC?

The financial health rating of AMGEN INC (AMGN) is 3 / 10.